Response to Forman et al.’s “A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.”

Nanxiang Zhang, Meirong Xu